Cover

Congenital Endocrinopathies

New Insights into Endocrine Diseases and Diabetes
Workshop, Genova, January 2007

Editor(s): Lorini R. (Genova) 
Maghnie M. (Genova) 
D'Annunzio G. (Genova) 
Loche S. (Cagliari) 
Savage M.O. (London) 
Table of Contents
Vol. 11, No. , 2007
Section title: Paper
Lorini R, Maghnie M, D’Annunzio G, Loche S, Savage MO (eds): Congenital Endocrinopathies. New Insights into Endocrine Diseases and Diabetes. Endocr Dev. Basel, Karger, 2007, vol 11, pp 122-132
(DOI:10.1159/000111067)
Paper

A Clinical Approach to Severe Insulin Resistance

Savage D.a · Semple R.a · Chatterjee V.a · Wales J.b · Ross R.c · O'Rahilly S.a
aDepartments of Clinical Biochemistry and Medicine, University of Cambridge, Cambridge, and b Department of Paediatric Endocrinology, Sheffield Children’s Hospital, and c Department of Diabetes and Endocrinology, Northern General Hospital, Sheffield, UK

Abstract

Extreme forms of insulin resistance are a rare cause of type 2 diabetes. However, individuals with severe insulin resistance pose unique diagnostic and therapeutic challenges, and have often acted as ‘experiments of nature’ providing important novel information regarding endocrine physiology and mechanistic insights relevant to the study of more common disorders. Progress in understanding the molecular pathogenesis of such syndromes is also beginning to yield novel therapeutic options. Severe insulin resistance typically presents in 1 of 3 ways: (1) disordered glucose metabolism including both diabetes and/or paradoxical hypoglycaemia; (2) acanthosis nigricans, a velvety hyperpigmentation of axilliary and flexural skin often associated with skin tags; or (3) hyperandrogenism in girls (hirsutism, oligo-/amenorrhoea and polycystic ovaries). Lipodystrophy is a major cause of severe insulin resistance and needs to be looked for very carefully, particularly in the patients with significant dyslipidaemia and fatty liver. Specific treatments are now available for some forms of severe insulin resistance; for example, leptin replacement in patients with generalized lipodystrophy. In the absence of a specific diagnosis and therapy, metformin is a useful insulin sensitizer and should be used in conjunction with aggressive diet and exercise interventions.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.